Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
741 to 760 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nitric oxide inhibits FTO demethylase activity to regulate N6-methyladenosine mRNA methylation. | Redox Biol | 2023 | 37866163 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in kidney injury. | Clin Epigenetics | 2023 | 37865763 | PubTator, text mining | PubMed |
| Suppression of Wnt/β-catenin Signaling in PDAC via METTL16-mediated N6-methyladenosine Modification of DVL2. | J Cancer | 2023 | 37859814 | PubTator, text mining | PubMed |
| m6A reading protein RBMX as a biomarker for prognosis and tumor progression in esophageal cancer. | Transl Cancer Res | 2023 | 37859733 | PubTator, text mining | PubMed |
| ALKBH5 enhances lipid metabolism reprogramming by increasing stability of FABP5 to promote pancreatic neuroendocrine neoplasms progression in an m6A-IGF2BP2-dependent manner. | J Transl Med | 2023 | 37858219 | PubTator, text mining | PubMed |
| Exon Junction Complex Is a Molecular Compass of N6-Methyladenosine Modification. | Mol Cells | 2023 | 37853685 | PubTator, text mining | PubMed |
| Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. | Mol Cancer | 2023 | 37853437 | PubTator, text mining | PubMed |
| Crosstalk between m6A modification and alternative splicing during cancer progression. | Clin Transl Med | 2023 | 37850412 | PubTator, text mining | PubMed |
| ALKBH5 controls the meiosis-coupled mRNA clearance in oocytes by removing the N 6-methyladenosine methylation. | Nat Commun | 2023 | 37848452 | PubTator, text mining | PubMed |
| The mitochondrial fusion-associated protein MFN2 can be used as a novel prognostic molecule for clear cell renal cell carcinoma. | BMC Cancer | 2023 | 37845657 | PubTator, text mining | PubMed |
| Molecular subtypes based on N6-methyladenosine RNA methylation demonstrate the heterogeneity of immune and biological functions in pediatric septic shock. | Heliyon | 2023 | 37842565 | PubTator, text mining | PubMed |
| Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment. | Cancer Drug Resist | 2023 | 37842241 | PubTator, text mining | PubMed |
| The role of N6-methyladenosine (m6A) in kidney diseases. | Front Med (Lausanne) | 2023 | 37841018 | PubTator, text mining | PubMed |
| Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. | Cancer Cell Int | 2023 | 37840147 | PubTator, text mining | PubMed |
| Comprehensive Analysis of the Transcriptome-Wide m6A Methylome in Shaziling Pig Testicular Development. | Int J Mol Sci | 2023 | 37833923 | PubTator, text mining | PubMed |
| Low RNA stability signifies strong expression regulatability of tumor suppressors. | Nucleic Acids Res | 2023 | 37831104 | PubTator, text mining | PubMed |
| N6-methyladenosine modification-a key player in viral infection. | Cell Mol Biol Lett | 2023 | 37828480 | PubTator, text mining | PubMed |
| METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3. | Sci Rep | 2023 | 37828232 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification of lncRNA SNHG3 accelerates gastric cancer progression by modulating miR-186-5p/cyclinD2 axis. | Int J Immunopathol Pharmacol | 2023 | 37823387 | PubTator, text mining | PubMed |
| Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms. | Front Pharmacol | 2023 | 37822879 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=38